Indian firms have been focusing on complex generics for some time now, which insulates them partially from pricing pressures ...

Nomura India maintains 'Buy' rating on Cipla with Rs 1,780 target by March 2026. Cipla's Goa site receives USFDA approval for gAbraxane, paving way for FY26 launch. Launch expected in 1HFY26 ...

Cipla has secured USFDA approval to market a generic cancer treatment, specifically paclitaxel protein-bound particles.

Drugmaker Cipla on Tuesday announced that it has entered into an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals for the commercialization of clobetasol propionate ...

"Formosa Pharma welcomes this partnership with Cipla, a well-renowned and respected global pharmaceutical brand. We appreciate their recognition and desire to add APP13007 to their rich portfolio ...

Cipla Limited on Tuesday announced an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals for the commercialization of clobetasol propionate ophthalmic suspension, 0.05% ...

Pharma major Cipla will release its Q4 FY25 earnings on May 13, 2025. The Board may also consider a final dividend for FY25.

Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.

By Ana Swanson The White House on Thursday clarified that China faced a minimum tariff rate of 145 percent on all imports to the United States. A day earlier, President Trump had said that he was ...